Apatorsen

Drug Profile

Apatorsen

Alternative Names: ISIS-306053; OGX-427

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator University of British Columbia
  • Developer OncoGenex Pharmaceuticals; Sarah Cannon Research Institute
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action HSP27 heat shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Bladder cancer

Highest Development Phases

  • Phase II Non-small cell lung cancer; Pancreatic cancer; Prostate cancer
  • Suspended Bladder cancer
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 23 Feb 2017 Apatorsen is available for licensing as of 23 Feb 2017. 9211950
  • 18 Feb 2017 Efficacy data from the phase II Pacific trial in Prostate cancer and phase II Borealis-2 trial in Bladder cancer released by OncoGenex Pharmaceuticals ,
  • 16 Nov 2016 Suspended - Phase-II for Bladder cancer (Combination therapy, First-line therapy, Late-stage disease) in USA, Canada, France, Germany, Italy, Poland and Spain (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top